恆瑞醫藥(600276.SH):普瑞巴林緩釋片獲得藥品註冊證書
格隆匯9月29日丨恆瑞醫藥(600276.SH)公佈,近日,公司收到國家藥品監督管理局核准簽發的《藥品註冊證書》。藥物名稱:普瑞巴林緩釋片。
普瑞巴林是抑制性神經遞質γ-氨基丁酸(GABA)的結構衍生物,與中樞神經系統組織中α2-δ位點(電壓門控鈣通道的一個輔助性亞基)有高度親和力。普瑞巴林緩釋片主要適用於治療帶狀皰疹後神經痛。
普瑞巴林緩釋片由輝瑞公司開發,2017年10月在美國獲批上市,商品名為Lyrica®CR,用於治療糖尿病性外周神經病引起的神經性疼痛和帶狀皰疹後神經痛。目前,國內另有北京泰德製藥、上海宣泰醫藥已報產。除公司外,國內未見其他公司獲批上市信息。
經查詢,2020年普瑞巴林相關劑型全球銷售額約為28.26億美元。截至目前,普瑞巴林相關項目累計已投入研發費用約為2330萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.